title: Evidence for scaling up HIV treatment in sub-Saharan Africa: A call for incorporating health system constraints.
abstract: Jan Hontelez and colleagues argue that the cost-effectiveness studies of HIV treatment scale-up need to include health system constraints to be more informative.
authors.affiliation: Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands.
authors.forename: Evelinn
authors.initials: E
authors.lastname: Mikkelsen
authors.affiliation: Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts, United States of America.|Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.|Africa Centre for Population Health, University of KwaZulu-Natal, Mtubatuba, South Africa.
authors.forename: Jan A C
authors.identifier: 0000-0002-9323-7861
authors.initials: JA
authors.lastname: Hontelez
authors.affiliation: Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands.
authors.forename: Maarten P M
authors.initials: MP
authors.lastname: Jansen
authors.affiliation: Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts, United States of America.|Africa Centre for Population Health, University of KwaZulu-Natal, Mtubatuba, South Africa.|Institute of Public Health, Heidelberg University, Heidelberg, Germany.
authors.forename: Till
authors.initials: T
authors.lastname: Bärnighausen
authors.affiliation: School of Public Health, Imperial College London, London, United Kingdom.
authors.forename: Katharina
authors.identifier: 0000-0003-3138-4169
authors.initials: K
authors.lastname: Hauck
authors.affiliation: Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.|Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
authors.forename: Kjell A
authors.initials: KA
authors.lastname: Johansson
authors.affiliation: Center for Global Health and Development, Boston University, Boston, Massachusetts, United States of America.|Health Economics and Epidemiology Research Office, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
authors.forename: Gesine
authors.identifier: 0000-0003-0439-381X
authors.initials: G
authors.lastname: Meyer-Rath
authors.affiliation: Center for Global Development, Washington, District of Columbia, United States of America.
authors.forename: Mead
authors.identifier: 0000-0003-4311-2080
authors.initials: M
authors.lastname: Over
authors.affiliation: Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
authors.forename: Sake J
authors.initials: SJ
authors.lastname: de Vlas
authors.affiliation: Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands.
authors.forename: Gert J
authors.initials: GJ
authors.lastname: van der Wilt
authors.affiliation: Royal Tropical Institute (KIT), Amsterdam, the Netherlands.
authors.forename: Noor
authors.initials: N
authors.lastname: Tromp
authors.affiliation: Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands.
authors.forename: Leon
authors.identifier: 0000-0003-2252-0579
authors.initials: L
authors.lastname: Bijlmakers
authors.affiliation: Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands.
authors.forename: Rob M P M
authors.initials: RM
authors.lastname: Baltussen
mesh_terms: D017954:Africa South of the Sahara; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D011634:Public Health / Q000191:economics*
chemical_list: D019380:Anti-HIV Agents